FluoroPharma develops and commercializes proprietary medical diagnostic imaging products for use with positron emission tomography (PET). The company’s current focus is on the detection and assessment of acute and chronic forms of coronary artery disease (CAD), in addition to the detection of inflamed atherosclerotic plaque in peripheral arteries, and amyloid plaque in Alzheimer’s disease. Leading FluoroPharma’s development are its key executives:
• Thijs Spoor (Chairman & CEO) – Mr. Spoor previously held the title of CFO for Sunstone BioSciences. He holds a Nuclear Pharmacy degree from the University of Toronto as well as an M.B.A. from Columbia University with concentrations in finance and accounting. Mr. Spoor has been a guest lecturer at Columbia Business School, Kings College in London, and the University of Newcastle in Australia and has presented at medical grand rounds and psychiatric grand rounds at various hospitals on the role of brain imaging. Prior to joining Sunstone BioSciences, Mr. Spoor worked as a consultant at Oliver Wyman, focusing on helping pharmaceutical and medical device companies evaluate their global revenue potential given the complex interplay of regulatory approvals, the reimbursement environment, as well as the impact of physician preference within constantly evolving standards of care. He further specialized on the implications of healthcare reform on new product approval and health insurance reform.
• Boyan Goumnerov, MD (COO & VP Clinical Trials) – Prior to his appointment with FluoroPharma Dr. Goumnerov held executive positions in the healthcare and biomedical research fields, most recently as President of VasoStent, Inc. and managing director of CardioVas Inc.- start-up medical device companies targeting the field of intravascular cardiac imaging and therapy. His academic background includes research within the departments of Surgery and Molecular Biology at the Massachusetts General Hospital (MGH) and The Shriners Burn Hospital for Children, Boston, where he held academic appointments with Harvard Medical School. Dr. Goumnerov also did extensive work within the Department of Pathology/Neuropathology at Children’s Hospital Boston, in developing image analysis protocols for evaluation of neuromuscular diseases before moving to MGH. He is co-author of numerous scientific publications. Dr. Goumnerov obtained his M.D. from the Medical University of Sofia, Bulgaria, and worked as a clinician prior to relocating to the US.
• Tamara Rhein (CFO) – Ms. Rhein joined FluoroPharma in 2011 as Controller. Prior to FluoroPharma, she was Controller of Manhattan Pharmaceuticals, where, in addition to maintaining the critical financial functions for the company, she was also responsible for a wide range of activities including financial statement preparation, footnote disclosures for SEC filings, stock option accounting, and quarterly and year-end audits. Before Manhattan Pharmaceuticals, Ms. Rhein was with Vyteris, where her primary role was to manage the SEC accounting and reporting department. In addition to her financial responsibilities, Ms. Rhein worked with the CEO on the launch of a new product. In this capacity, she managed critical aspects of coordination, timing and tracking of the initiative. Before joining Vyteris, Ms. Rhein was Vice President of New Business at Credit Suisse First Boston, where she provided comprehensive research and analysis to guide Senior Management on certain projects and complex business transactions.
For more information, see the company website at www.FluoroPharma.com
Let us hear your thoughts below:
